KRAS and pancreatic neoplasm: This threshold, which is lower than the standard threshold of 5% MAF, was selected given that typical activating oncogenic mutations (e.g. mutant KRAS) are well defined in pancreatic cancer and EUS biopsies are likely to have a lower MAF than other sampling techniques due to presence of non-tumor cells within the biopsy (e.g. duodenal and gastric wall contaminants).